natgillin/translations-raw huggingface dataset:
Anti-arrhythmics and anti-seizure medicinal products Patients taking anti-arrhythmic medicinal products for the control of arrhythmias and anti-seizure medicinal products for the control of seizure disorders were excluded from clinical trials.
Antiaritmiki in antiepileptična zdravila za nadzor epileptičnih napadov Bolniki, ki jemljejo antiaritmična zdravila za nadzor aritmij in antiepileptična zdravila za nadzor epileptičnih napadov, so bili izključeni iz kliničnih preskušanj.
Closer monitoring of serum bicarbonate levels is therefore recommended.
Zato se priporoča skrbno nadziranje ravni hidrogenkarbonata v serumu.
In clinical trials mean total and LDL cholesterol declined by 15-31%.
Pri kliničnih preskušanjih je povprečna vrednost skupnega holesterola in holesterola LDL upadla za 1531 %.
Tasermity should only be given to pregnant or breast-feeding women if clearly needed.
Zdravilo Tasermity se sme dajati nosečnicam ali doječim ženskam le, kadar je nujno potrebno.
Sevelamer hydrochloride has been given to normal healthy volunteers in doses up to 14 grams, the equivalent of seventeen 800 mg tablets, per day for eight days with no undesirable effects.
Sevelamerijev klorid so dajali zdravim prostovoljcem v odmerkih do 14 gramov na dan, kar je enakovredno petintridesetim tabletam po 800 mg, osem dni zaporedoma brez neželenih učinkov.
Consequently, sevelamer hydrochloride should not be taken simultaneously with ciprofloxacin.
Zato se sevelamerijev klorid ne sme jemati istočasno s ciprofloksacinom.
Each bottle contains 180 film-coated tablets.
Ena plastenka vsebuje 180 filmsko obloženih tablet.
Peritonitis is a known complication in patients receiving peritoneal dialysis (PD) and in a clinical study with sevelamer hydrochloride, a number of peritonitis cases were reported.
Peritonitis je znan zaplet pri bolnikih, ki prejemajo peritonealno dializo (PD), in v kliničnih študijah s sevelamerijevim kloridom so poročali o številnih primerih peritonitisa.
The average actual daily dose used in the chronic phase of a one year clinical study was 7 grams of sevelamer hydrochloride.
Povprečni dnevni odmerek sevelamerijevega klorida, ki so ga v enoletni klinični študiji dajali bolnikom v kronični fazi, je bil 7 gramov.
In interaction studies in healthy volunteers, sevelamer hydrochloride had no effect on the bioavailability of digoxin, warfarin, enalapril or metoprolol.
Ko so preučevali medsebojno delovanje pri zdravih prostovoljcih, sevelamerijev klorid ni imel učinka na biološko uporabnost digoksina, varfarina, enalaprila ali metoprolola.
In interaction studies in healthy volunteers, sevelamer hydrochloride decreased the bioavailability of ciprofloxacin by approximately 50% when co-administered with sevelamer hydrochloride in a single dose study.
V študijah medsebojnega delovanja pri zdravih prostovoljcih je sevelamerijev klorid zmanjšal biološko uporabnost ciprofloksacina za približno 50 % pri sočasni uporabi z zdravilom Tasermity v študiji z enim odmerkom.
The safety and efficacy in children (below the age of 18 years) have not been studied.
Varnosti in učinkovitosti zdravila Tasermity pri otrocih (starih do 18 let) niso preučevali.
- The other ingredients are silica colloidal anhydrous and stearic acid, hypromellose (E464), diacetylated monoglycerides, iron oxide black (E172) and propylene glycol.
- Pomožne snovi so brezvodni koloidni silicijev dioksid in stearinska kislina, hipromeloza (E464), diacetilirani monogliceridi, črni železov oksid (E172) in propilenglikol.
Serum calcium levels should be monitored as is done in normal follow-up of a dialysis patient.
Nadzirati je treba ravni kalcija v serumu kot pri običajnem spremljanju bolnikov na dializi.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING LABEL with Blue Box - 1 BOTTLE OF 180 TABLETS 800 mg WITHOUT OUTER CARTON
NALEPKA s tako imenovanim modrim okencem - 1 PLASTENKA S 180 TABLETAMI PO 800 mg BREZ ZUNANJE OVOJNINE
Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu.
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu.
When you switch from another phosphate binder to Tasermity, your doctor might consider monitoring the levels of bicarbonate in your blood more closely because Tasermity may decrease the levels of bicarbonate.
Pri prehodu z drugega fosfatnega vezalca na zdravilo Tasermity je priporočljivo, da vaš zdravnik pazljiveje spremlja ravni hidrogenkarbonata v krvi, ker zdravilo Tasermity te ravni lahko zniža.
Additional monitoring of vitamins and folic acid is recommended in patients receiving peritoneal dialysis, since in the clinical study, vitamin A, D, E and K levels were not measured in these patients.
Pri bolnikih na peritonealni dializi se priporoča dodatno nadziranje vitaminov in folne kisline, saj v klinični študiji ravni vitaminov A, D, E in K pri teh bolnikih niso merili.
However, in vitro and in vivo studies have indicated that sevelamer does not have genotoxic potential.
Vendar pa so in vitro in in vivo raziskave pokazale, da sevelamer ni genotoksičen.
The possibility of an interaction cannot be excluded and a close monitoring of blood concentrations of mycophenolate mofetil, ciclosporin and tacrolimus should be considered during the use of combination and after its withdrawal.
Možnost medsebojnega delovanja torej ni izključena, zato skrbno spremljajte koncentracije mikofenolat mofetila, ciklosporina in takrolimusa v krvi med uporabo te kombinacije in po njeni ukinitvi, če je potrebno.
What Tasermity looks like and contents of the pack
Izgled zdravila Tasermity in vsebina pakiranja
If you have missed one dose, this dose should be omitted and the next dose should be taken at the usual time with a meal.
Če pozabite vzeti odmerek, ga izpustite in naslednji odmerek vzemite kot običajno.
What Tasermity is and what it is used for
Kaj je zdravilo Tasermity in za kaj ga uporabljamo
In preclinical studies in rats and dogs, sevelamer at a dose of 10 times the maximum human doses reduced absorption of fat soluble vitamins D, E and K, and folic acid.
V predkliničnih raziskavah na podganah in psih je sevelamer v odmerku, ki je desetkrat večji od najvišjih odmerkov za ljudi, zmanjševal absorpcijo v maščobi topnih vitaminov D, E in K ter folne fisline.
A. MANUFACTURERS RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE
IZDELOVALCI, ODGOVORNI ZA SPROŠČANJE SERIJ POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z
In the clinical studies in haemodialysis patients, sevelamer hydrochloride alone did not have a consistent and clinically significant effect on serum intact parathyroid hormone (iPTH).
Med kliničnimi študijami pri bolnikih, ki se zdravijo s hemodializo, sam sevelamerijev klorid ni imel trajnega in klinično pomembnega učinka na intaktni paratiroidni hormon (iPTH).
• if you have swallowing problems
• imate težave s požiranjem
Pack size: 1 bottle of 180 tablets
Velikosti pakiranj so: 1 plastenka s 180 tabletami
Sevelamer hydrochloride should only be given to breast-feeding women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the infant (see section 5.3).
Sevelamerijev klorid naj doječe ženske jemljejo le, če ga nujno potrebujejo in po skrbni analizi tveganja/koristi za mater in dojenčka (glejte poglavje 5.3).
For patients previously on phosphate binders, Sevelamer hydrochloride should be given on a gram for gram basis with monitoring of serum phosphorus levels to ensure optimal daily doses.
Bolnikom, ki so prej jemali vezalce fosfata, je treba sevelamerijev klorid dajati na osnovi gram po gram ter pri tem nadzirati ravni fosforja v serumu, da se zagotovijo optimalni dnevni odmerki.
Do not store this medicine above 25 °C.
Zdravilo shranjujte pri temperaturi do 25 C.
Always take this medicine exactly as your doctor has told you.
Pri jemanju tega zdravila vedno natančno upoštevajte navodila zdravnika.
Efficacy and safety of sevelamer hydrochloride has not been studied in patients with:
Učinkovitost in varnost sevelamerijevega klorida nista bili preučevani pri bolnikih s/z:
The safety of Tasermity has not been established in pregnant or breast-feeding women.
Varnosti zdravila Tasermity pri nosečnicah ali doječih ženskah niso ugotavljali.
Although no clinically significant serum chloride increase has been observed in the clinical studies, serum chloride should be monitored as is done in the routine follow-up of a dialysis patient.
Čeprav med kliničnimi študijami ni bilo opaziti klinično pomembnega porasta koncentracije klorida v serumu, je potrebno klorid v serumu spremljati kot pri postopku pri bolniku na dializi.
The most frequently occurring (≥5% of patients) adverse reactions were all in the gastrointestinal disorders system organ class.
Povzetek varnostnega profila Najpogostejši neželeni učinki (≥ 5 % bolnikov) so bili vsi v organskem sistemu bolezni prebavil.
Iron oxide black (E172) Propylene glycol Hypromellose (E464)
Tiskarsko črnilo: črni železov oksid (E172), propilenglikol, hipromeloza (E464).
Serum phosphate level in patients not on
Raven fosfata v serumu pri bolnikih, ki ne
You may develop peritonitis (infection of your abdominal fluid) associated with your peritoneal dialysis.
Pri vas se lahko razvije peritonitis (okužba vaše trebušne tekočine) zaradi peritoenalne dialize.
Sevelamer hydrochloride has no or negligible influence on the ability to drive and use machines.
Sevelamerijev klorid nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
Adult patients whose kidneys have failed and who are undergoing haemodialysis or peritoneal dialysis are not able to control the level of serum phosphate in their blood.
Odrasli bolniki z odpovedjo ledvic, ki so na hemodializi ali peritonealni dializi, ne morejo uravnavati ravni serumskih fosfatov v krvi.
Tasermity tablets are film-coated, off-white, oval tablets with “SH800” imprinted on one side.
Zdravilo Tasermity tablete so sivo-bele, ovalne, filmsko obložene tablete z natisnjeno oznako "SH800” na eni strani.
Patients with renal insufficiency may develop hypocalcaemia or hypercalcaemia.
Pri bolnikih z ledvično okvaro lahko pride do hipokalciemije ali hiperkalciemije.
In the 12 week study involving peritoneal dialysis patients however, similar iPTH reductions were seen compared with patients receiving calcium acetate.
V 12 tedenski študiji, ki je zajemala bolnike, ki so prejemali peritonealno dializo pa se je pokazala primerljivost zmajšanja iPTH-ja z bolniki, ki so prejemali kalcijev acetat.
Tasermity contains sevelamer, a non-absorbed phosphate binding poly (allylamine hydrochloride) polymer, free of metal and calcium.
Zdravilo Tasermity vsebuje sevelamer, neabsorbiran polimer (alilaminijev klorid), ki veže fosfate, brez kovine in kalcija.
• The effects of medicines such as ciclosporin, mycophenolate mofetil and tacrolimus (medicines used in transplant patients) may be reduced by Tasermity.
• Učinke zdravil kot so ciklosporin, mofetilmikofenolat in takrolimus (zdravila, ki zavirajo odziv imunskega sistema), lahko zdravilo Tasermity zmanjša.
Patients taking Tasermity should adhere to their prescribed diet and liquid intake.
Bolniki, ki jemljejo zdravilo Tasermity, se morajo držati predpisane diete.
Closer monitoring of TSH levels is therefore recommended in patients receiving both medicinal products.
Zato se pri bolnikih, ki jemljejo obe zdravili, priporoča skrbno nadziranje ravni TSH.
• develop a low or high level of calcium in your blood.
• koncentracija kalcija v krvi pade ali naraste.
• if you have undergone major surgery on your stomach or bowel.
• ste prestali zahtevnejše operacije želodca ali črevesja.
Worsening of acidosis has been reported upon switching from other phosphate binders to sevelamer in a number of studies where lower bicarbonate levels in the sevelamer-treated patients compared to patients treated with calcium-based binders were observed.
V številnih študijah so poročali o poslabšanju acidoze po prehodu iz drugih vezalcev fosfata na sevelamer, kjer so opazili nižje ravni hidrogenkarbonata pri bolnikih, zdravljenih s sevelamerom v primerjavi z bolniki, zdravljenimi z vezalci na osnovi kalcija.
Closer monitoring of patients with hypothyroidism co-administered with sevelamer hydrochloride and levothyroxine is recommended (see section 4.5).
Priporoča se skrbno nadziranje bolnikov s hipotiroidizmom, ki dobivajo sevelamerijev klorid sočasno z levotriroksinom (glejte poglavje 4.5).
The safety and efficacy of this product have not been established in patients below the age of 18 years.
Pediatrična populacija Varnost in učinkovitost tega zdravila pri otrocih, mlajših od 18 let, nista bili ugotovljeni.
Sevelamer hydrochloride should only be given to pregnant women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the foetus (see section 5.3).
Sevelamerijev klorid naj nosečnice jemljejo le, če ga nujno potrebujejo, in po skrbni analizi tveganja/koristi za mater in zarodek (glejte poglavje 5.3).
Ciclosporin, mycophenolate mofetil and tacrolimus in transplant patients Reduced levels of ciclosporin, mycophenolate mofetil and tacrolimus have been reported in transplant patients when coadministered with sevelamer hydrochloride without any clinical consequences (i.e graft rejection).
Ciklosporin, mofetilmikofenolat in takrolimus pri bolnikih po presaditvi Pri bolnikih po presaditvi, ki so sočasno prejemali sevelamerijev klorid, so poročali o zmanjšanih koncentracijah ciklosporina, mikofenolat mofetila in takrolimusa, vendar brez kakršnihkoli kliničnih posledic (npr. zavrnitev presadka).
Sevelamer hydrochloride alone is not indicated for the control of hyperparathyroidism.
Sevelamerijev klorid samo ni namenjeno za nadzorovanje hiperparatiroidizma.
Therefore Tasermity is not recommended for use in this population.
Zato uporaba zdravila Tasermity pri otrocih ni priporočljiva.
Patients who are constipated should be monitored carefully while being treated with sevelamer hydrochloride.
Zaprte bolnike je potrebno med zdravljenjem s sevelamerijevim kloridom skrbno spremljati.
Sevelamer hydrochloride does not contain calcium.
Sevelamerijev klorid ne vsebuje kalcija.
In very rare cases, intestinal obstruction and ileus/subileus have been observed in patients during treatment with sevelamer hydrochloride.
V zelo redkih primerih je bilo pri bolnikih med zdravljenjem s sevelamerijevim kloridom opaziti črevesno zaporo in ileus/subileus.
Film-coated tablet (tablet) The off-white, oval tablets are imprinted with “SH800” on one side.
filmsko obložena tableta (tableta) Sivobele ovalne tablete imajo na eni strani natisnjeno oznako “SH800”.
- If you get any side effects talk to your doctor or pharmacist.
- Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom ali s farmacevtom.
• gastrointestinal motility disorders including untreated or severe gastroparesis, diverticulosis,
• gastrointestinalnimi motnjami, vključno z nezdravljeno ali hudo gastroparezo, divertikulozo in zastajanjem hrane v želodcu in nenormalnim ali nepravilnim gibanjem črevesja
HDPE bottles, with a child resistant polypropylene closure and a foil induction seal.
HDPE plastenke s pokrovom iz polipropilena, ki otrokom onemogoči odpiranje, in indukcijskim tesnilom iz folije.
Folate deficiency
Pomanjkanje folatov
Caution should be exercised when prescribing sevelamer hydrochloride to patients also taking these medicinal products.
Pri predpisovanju sevelamerijevega klorida bolnikom, ki jemljejo tudi omenjena zdravila, je potrebna previdnost.
In a study in rats, administering sevelamer in 15-30 x the human dose, an increase in serum copper was detected.
V raziskavah na podganah so pri dajanju sevelamera v 15 do 30-krat večjem odmerku kot za ljudi zabeležili porast bakra v serumu.
• if you are not on dialysis
• se ne zdravite z dializo
In a clinical trial of one-year duration, sevelamer hydrochloride had no adverse effect on bone turnover or mineralisation compared to calcium carbonate.
V enoletnih kliničnih preskusih sevelamerijev klorid na obnovo in mineralizacijo kosti v primerjavi s kalcijevim karbonatom ni imelo neugodnih učinkov.
By binding phosphate in the gastrointestinal tract, sevelamer lowers the phosphate concentration in the serum.
Ker veže fosfate v prebavilih, sevelamer znižuje koncentracijo fosfata v serumu.
Hypromellose (E464) Diacetylated monoglycerides
Hipromeloza (E464),
In parallel design studies involving 244 haemodialysis patients with treatment duration of up to 54 weeks and 97 peritoneal dialysis patients with treatment duration of 12 weeks were conducted Adverse reactions from these studies (299 patients), from uncontrolled clinical trials (384 patients) and that were spontaneously reported from post-marketing experience are listed by frequency in the table below.
Neželeni učinki iz teh študij (299 bolnikov), iz nekontroliranih kliničnih preskušanj (384 bolnikov) in tisti, o katerih so spontano poročali po začetku trženja, so glede na pogostost našteti v spodnji preglednici.
• if you have symptoms of delayed emptying of stomach contents such as feeling of fullness,
• imate simptome zapoznelega praznjenja želodčne vsebine, ki se občutijo kot polnost v želodcu, slabost in/ali bruhanje
The tablets are packed in high density polyethylene bottles with a child resistant polypropylene closure and an induction seal.
Tablete so pakirane v plastenkah iz polietilena visoke gostote, s pokrovčkom iz polipropilena, ki je varen za otroke, in indukcijskim tesnilom.
In the event of a possible overdose you should contact your doctor immediately.
Če ste vzeli večji odmerek zdravila Tasermity, kot bi smeli V primeru prevelikega odmerka se takoj posvetujte z vašim zdravnikom.
Serum chloride may increase during sevelamer hydrochloride treatment as chloride may be exchanged for phosphorus in the intestinal lumen.
Med zdravljenjem s sevelamerijevim kloridom lahko pride do porasta koncentracije klorida v serumu, ker lahko fosfor zamenja klorid v črevesnem lumnu.
Do not crush, chew or break into pieces prior to swallowing.
Tablet ne drobite, ne žvečite in ne lomite na koščke.
Tasermity 800 mg film-coated tablets
IME ZDRAVILA Tasermity 800 mg filmsko obložene tablete
Tasermity is unlikely to affect your ability to drive or to use machines.
Vpliv na sposobnost upravljanja vozil in strojev Ni verjetno, da bi zdravilo Tasermity vplivalo na vašo sposobnost vožnje in upravljanja s stroji.
It binds phosphate from food in the digestive tract and so reduces serum phosphate levels in the blood.
Zdravilo Tasermity veže fosfate iz hrane v prebavnem traktu in tako zniža koncentracijo serumskega fosfata v krvi.
• If you are taking medicines for heart rhythm problems or for epilepsy, you should consult your doctor before taking Tasermity.
• Če jemljete zdravila zaradi težav s srčnim ritmom ali zaradi epilepsije, se o jemanju zdravila
Dialysis Interaction studies have not been conducted in patients on dialysis.
Dializa Pri bolnikih, ki se zdravijo z dializo, študij medsebojnega delovanja niso izvedli.
• have a low amount of vitamin D in your blood.
• vsebnost vitamina D v krvi pade, odvisno od vrste ledvičnih težav.
During post marketing experience, very rare cases of increased thyroid stimulating hormone (TSH) levels have been reported in patients co-administered sevelamer hydrochloride and levothyroxine.
V izkušnjah po začetku trženja so poročali o zelo redkih primerih zvišanih ravni tiroideo stimulirajočega hormona (TSH) pri bolnikih, ki so sočasno jemali sevelamerijev klorid in levotiroksin.
Tasermity contains sevelamer as the active ingredient.
Zdravilo Tasermity vsebuje zdravilno učinkovino sevelamer.
The safety of sevelamer hydrochloride has not been established in pregnant women.
Varnosti sevelamerijevega klorida pri nosečnicah niso ugotavljali.
How to take Tasermity
Kako jemati zdravilo Tasermity
Tasermity 800 mg film-coated tablets sevelamer hydrochloride
Tasermity 800 mg filmsko obložene tablete sevelamerijev klorid
In clinical trials, sevelamer hydrochloride has been shown to be effective in reducing serum phosphorus in patients receiving haemodialysis or peritoneal dialysis.
Klinične študije dokazujejo učinkovitost sevelamerijevega klorida pri zmanjševanju serumskega fosfata pri bolnikih, ki prejemajo hemodializo oziroma peritonealno dializo.
Starting dose of Sevelamer hydrochloride 800 mg tablets
Začetni odmerek sevelamerijevega klorida 800 mg tablete
Tasermity is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.
Zdravilo Tasermity je namenjen uravnavanju hiperfosfatemije pri zdravljenju odraslih bolnikov, ki prejemajo hemodializo oziroma peritonealno dializo.
Talk to your doctor before taking Tasermity if any of the following applies to you:
Opozorila in previdnostni ukrepi Če karkoli od naštetega velja za vas, se pred začetkom jemanja zdravila Tasermity posvetujte z zdravnikom:
In patients with secondary hyperparathyroidism sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to lower the intact parathyroid hormone (iPTH) levels.
Pri bolnikih s sekundarnim hiperparatiroidizmom je treba sevelamerijev klorid uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijeve dodatke, 1,25 - dihidroksi vitamin D3 ali kakšen njegov analog, za znižanje koncentracije intaktnega paratiroidnega hormona (iPTH).
In patients with secondary hyperparathyroidism sevelamer hydrochloride should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25-dihydroxy Vitamin D3 or one of its analogues to lower the iPTH levels.
Pri bolnikih s sekundarnim hiperparatiroidizmom je treba sevelamerijev klorid uporabljati v smislu večstranskega pristopa zdravljenja, ki lahko vključuje kalcijeve dodatke, 1,25 - dihidroksi vitamin D3 ali kakšen njegov analog, za znižanje koncentracije iPTH.
What you need to know before you take Tasermity Do not take Tasermity:
Kaj morate vedeti, preden boste vzeli zdravilo Tasermity
Studies in animals have shown that sevelamer did not impair fertility in male or female rats at exposures at a human equivalent dose
Študije na živalih so pokazale, da sevelamer ne vpliva na plodnost pri samcih in samičkah podgan pri izpostavljenosti primerjalnemu odmerku pri človeku, dvakrat večjemu od največjega odmerka v kliničnem preskušanju 13 g/dan, na osnovi relativne površine telesa.
During post-marketing experience, very rare cases of increased phosphate levels have been reported in patients taking proton pump inhibitors co-administered with sevelamer hydrochloride.
Med izkušnjami v obdobju trženja so poročali o zelo redkih primerih zvišanih ravni fosforja pri bolnikih, ki so sočasno jemali sevelamerijev klorid in zaviralce protonske črpalke.
Patients should take sevelamer hydrochloride with meals and adhere to their prescribed diets.
Bolniki morajo jemati sevelamerijev klorid ob obroku in se držati predpisanih diet. Tablete je treba pogoltniti cele.
If you do not take multivitamin supplements you may also develop low levels of vitamins A, E, K and folic acid in your blood and therefore your doctor may monitor these levels and prescribe supplemental
Zato utegne vaš zdravnik nadzirati koncentracijo vitamina D v krvi in vam po potrebi predpisati dodatek vitamina D. Če ne jemljete multivitaminskih dodatkov, vam lahko pade tudi koncentracija vitaminov A, E, K in folne kisline v krvi, zato utegne vaš zdravnik nadzirati tudi te koncentracije in vam po potrebi predpisati dodatne vitamine.
Each tablet contains 800 mg sevelamer hydrochloride.
Ena tableta zdravila Tasermity vsebuje 800 mg sevelamerijevega klorida.
Tasermity is used to control the levels of phosphate in the blood of adult kidney failure patients on haemodialysis or peritoneal dialysis treatment.
Zdravilo Tasermity se uporablja za uravnavanje koncentracije fosfatov v krvi pri odraslih bolnikih s kronično ledvično odpovedjo, ki se zdravijo s hemodializo oziroma peritonealno dializo.